LACK OF EVIDENCE FOR A VIABLE MICROBIOTA IN MURINE AMNIOTIC FLUID

RUNNING TITLE: AMNIOTIC FLUID LACKS A MICROBIOTA

Andrew D. Winters^{a,b,c}, Roberto Romero^{a,d-h}, Jonathan M. Greenberg^{a,i}, Jose Galaz^{a,i}, Zachary Shaffer^{a,j}, Valeria Garcia-Flores^{a,i}, David J. Kracht^{a,i}, Nardhy Gomez-Lopez^{a-c,i*}, and Kevin R. Theis^{a-c,i*}

AUTHOR AFFILIATIONS

^a Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, and Detroit, MI, Detroit, Michigan, USA.

^b Perinatal Research Initiative in Maternal, Perinatal and Child Health, Wayne State University School of Medicine, Detroit, Michigan, USA.

^c Department of Biochemistry, Microbiology, and Immunology, Wayne State University School of Medicine, Detroit, Michigan, USA.

^d Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan, USA. ^e Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, Michigan, USA.

^f Center for Molecular Medicine and Genetics, Wayne State University, Detroit, Michigan, USA.

^g Detroit Medical Center, Detroit, Michigan, USA.

^h Department of Obstetrics and Gynecology, Florida International University, Miami, Florida, USA

ⁱ Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, USA.

^j MD/PhD Combined Degree Program, Wayne State University School of Medicine, Detroit, Michigan, USA.

CORRESPONDING AUTHOR(S)

*Kevin R. Theis, PhD, Department of Biochemistry, Microbiology, and Immunology, Wayne State University School of Medicine, 540 East Canfield, Detroit, MI 48201, USA, Tel (313) 577-0877, Email: ktheis@med.wayne.edu

*Nardhy Gomez-Lopez, PhD, Department of Obstetrics and Gynecology, Wayne State University School of Medicine, 275 E. Hancock, Detroit, MI 48201, USA, Tel (313) 577-8904, Email: ngomezlo@med.wayne.edu

FUNDING SOURCES STATEMENT

This research was supported, in part, by the Perinatology Research Branch (PRB), Division of Intramural Research, *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, National Institutes of Health, U. S. Department of Health and Human Services (NICHD/NIH/DHHS), and, in part, with federal funds from the NICHD/NIH/DHHS under Contract No. HHSN275201300006C. This research was also supported by the Wayne State University Perinatal Initiative in Maternal, Perinatal and Child Health. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr. Romero has contributed to this work as part of his official duties as an employee of the United States Federal Government.

WORD COUNT OF ABSTRACT – 250

WORD COUNT OF TEXT – 150

ABSTRACT

The existence of an amniotic fluid microbiota (i.e., a viable microbial community) in mammals is controversial. Its existence would require a fundamental reconsideration of the role of intra-amniotic microbes in fetal development and pregnancy outcomes. In this study, we determined whether the amniotic fluid of mice harbors a microbiota in late gestation. Bacterial profiles of amniotic fluids located proximally or distally to the cervix were characterized through quantitative real-time PCR, 16S rRNA gene sequencing, and culture (N = 21 mice). These profiles were compared to those of technical controls for background DNA contamination. The load of 16S rDNA in the amniotic fluid exceeded that in controls. Additionally, the 16S rDNA profiles of the amniotic fluid differed from those of controls, with *Corynebacterium tuberculostearicum* being differentially more abundant in amniotic fluid profiles; however, this bacterium was not cultured. Of the 42 total bacterial cultures of amniotic fluids, only one yielded bacterial growth – *Lactobacillus murinus*. The 16S rRNA gene of this common murine-associated bacterium was not detected in any amniotic fluid sample, suggesting it did not originate from the amniotic fluid. No differences in 16S rDNA load, 16S rDNA profile, or bacterial culture were observed between amniotic fluids located proximal and distal to the cervix. Collectively, these data show that, although there is a modest DNA signal of bacteria in murine amniotic fluid, there is no evidence that this signal represents a viable microbiota. These findings refute the proposed role of amniotic fluid as a source of microorganisms for *in utero* colonization.

IMPORTANCE

The prevailing paradigm in obstetrics has been the sterile womb hypothesis, which posits that fetuses are first colonized by microorganisms during labor and/or the vaginal delivery process. However, it has been suggested that fetuses are consistently colonized *in utero*. One proposed source of colonizers is the amniotic fluid surrounding the fetus. This concept has been derived primarily from investigations that relied on DNA sequencing. Due to the low microbial biomass of amniotic fluid, such studies are susceptible to influences of background DNA contamination. Additionally, even if there is a microbial DNA signature in amniotic fluid, this is not necessarily reflective of a resident microbiota that could colonize the mammalian fetus. In the current study, using multiple microbiologic approaches and incorporating technical controls for DNA contamination, we show that, although there is a low abundance bacterial DNA signal in amniotic fluid, this does not translate to the presence of viable bacteria.

KEY WORDS: microbiome, low microbial biomass sample, pregnancy, *in utero* colonization, sterile womb hypothesis, mouse model

INTRODUCTION

The mammalian amniotic cavity is filled with a protective liquid (i.e., amniotic fluid) that surrounds the fetus throughout gestation. Indeed, the amniotic fluid is essential for fetal development and maturation [1, 2]. As such, the amniotic fluid is enriched with nutrients and growth factors [1, 3-5] and contains soluble (e.g. cytokines [6-27], anti-microbial molecules, etc. [28-33]) and cellular (e.g. innate and adaptive immune cells [34-40]) components that serve as an immunological barrier against invading pathogens. In clinical medicine, the amniotic fluid is utilized as a diagnostic tool for assessing intra-amniotic inflammation and/or infection [41-59], a condition that is strongly associated with obstetrical disease, the most detrimental of which is preterm birth [60]. Therefore, the presence of microorganisms in the amniotic fluid is associated with adverse maternal and neonatal outcomes [61-67], and the traditional view in obstetrics has been the “sterile womb hypothesis”, which proposes that the fetal environment is sterile and that the neonate first acquires a microbiota during the birthing process [68]. However, recent investigations have posited that the amniotic fluid harbors a resident microbiota, which functions as a primary source of microorganisms for initial colonization of the offspring *in utero* [69-77]. These juxtaposed views have sparked much debate [78-83].

Investigations of human amniotic fluid in normal pregnancy have yielded contradictory results. Multiple studies using DNA sequencing techniques [72, 75-77, 84, 85] and/or quantitative real-time PCR [70, 76] have identified an amniotic fluid microbiota; however, only one of these studies has demonstrated viable microorganisms from amniotic fluid through culture [72] (Table 1). To date, no study has used cultivation, qPCR, and DNA sequencing concurrently to confirm microbial presence in human amniotic fluid during normal pregnancy. The concurrent use of multiple microbiological techniques in such investigations is important because a

molecular signal of microorganisms is not necessarily equivalent to a true and viable microbiota [68, 70, 86-88]. For instance, the molecular signal may simply reflect circulating microbial DNA fragments [89]. Furthermore, if there is an amniotic fluid microbiota, it has a very low microbial biomass and, therefore, reliance on molecular techniques such as DNA sequencing to characterize the presumed microbiota is susceptible to influences of background DNA contamination from laboratory environments, DNA extraction kits, PCR reagents, etc. [90]. Yet, very few of the prior investigations that used DNA sequencing techniques to conclude the existence of a human amniotic fluid microbiota incorporated technical controls for background DNA contamination into their analyses [75, 76, 84, 91, 92] (Table 1). Hence, there remains uncertainty as to whether the human amniotic fluid harbors a microbiota.

The existence of an amniotic fluid microbiota would require a fundamental reconsideration of the role of intra-amniotic microorganisms in fetal development and pregnancy outcomes. Such reconsideration would require the implementation of animal models to perform mechanistic experimentation of host immune-microbe interactions. Yet, there have been only a limited number of studies investigating the presence of an amniotic fluid microbiota in animal models, specifically cattle, horses, sheep, goats, and rats (Table 2). Although each of these studies used DNA sequencing techniques, very few included qPCR, technical controls for background DNA contamination, or culture. Therefore, the objective of the current study was to determine whether the amniotic fluid of mice, the most widely utilized system for studying host immune-microbe interactions [93], harbors a microbiota using technical controls, qPCR, 16S rRNA gene sequencing, and bacterial culture.

RESULTS

Does the murine amniotic fluid contain 16S rDNA?

Amniotic fluid was collected from amniotic sacs located proximally and distally to the cervix under aseptic conditions from 13.5 – 18.5 days *post coitum* (dpc) (**Figure 1**). First, we evaluated the absolute abundance of 16S rDNA in amniotic fluid using qPCR. There was a significantly higher 16S rDNA signal in proximal ($W = 6$, $p = 0.0003$) and distal ($U = 16$, $p = 0.004$) amniotic fluid samples than in blank extraction controls. However, the 16S rDNA signal did not differ between paired proximal and distal samples ($V = 89$, $p = 0.571$) (**Figure 2A**). These results indicate that the murine amniotic fluid contains 16S rDNA, and that its concentrations do not depend on proximity to the cervix.

Does the 16S rDNA profile differ between murine amniotic fluid and controls?

Next, the 16S rDNA profiles of the amniotic fluid samples were characterized using nucleotide sequencing and the generation of amplicon sequence variants (ASVs). Prior to removing potential contaminants, the 16S rDNA profiles of both the proximal and distal amniotic fluid samples differed from that of negative controls (PERMANOVA $F = 2.343$, $R^2 = 0.068$, $p = 0.0001$ and $F = 1.806$, $R^2 = 0.052$, $p = 0.008$, respectively) (**Figure 2B**). The most prominent ASVs in the proximal and distal amniotic fluid samples and technical controls were *Staphylococcus*, *Pseudomonas*, and *Enterobacteriaceae* (ASVs 4, 6, and 7, respectively) (**Figure 2C**). Nevertheless, there were differentially abundant taxa between the amniotic fluid samples and negative controls (**Figure 3A and 3B**). Specifically, multiple ASVs classified as *Corynebacterium* were more abundant in proximal (ASV 10) and distal (ASVs 10, 31 and 572) amniotic fluid samples than in controls (**Figure 3A and 3B**). These corynebacteria were most

closely related to *C. tuberculostearicum*, *C. mucifaciens*, *C. ureicelerivorans*, *C. ihumii*, and *C. pilbarens* (**Figure 3C**). Additional taxa that were differentially abundant in proximal amniotic fluid samples compared to controls were *Streptococcus* (ASV 13) *Pseudomonas* (ASV 24), and *Sphingobium* (ASV 33) (**Figure 3A**). However, these signals may still represent contamination.

To address potential background DNA contamination, the program *decontam* was used in part to identify and remove likely contaminants. After contaminants were removed from the dataset, the ASVs with the highest mean relative abundance in both proximal and distal amniotic fluid samples were *Corynebacterium* and *Streptococcus* (ASVs 10 and 13, respectively) (**Figure 4A**). This is in contrast to the profile structure before contaminant removal (**Figure 2C**). The 16S rDNA profiles of paired proximal and distal amniotic fluid samples did not differ in richness (Chao1 richness) ($V = 58$, $p = 0.083$) or in evenness (Shannon-Wiener diversity) ($V = 76$, $p = 0.294$). The structure of these profiles did not differ either by mouse ID (PERMANOVA $F = 0.992$, $R^2 = 0.495$, $p = 0.551$) or proximity to the cervix ($F = 1.215$, $R^2 = 0.030$, $p = 0.089$) (**Figure 4B**). Collectively, these results indicate that, if there is a murine amniotic fluid microbiota, it is largely comprised of *Corynebacterium* and *Streptococcus*, both of which are readily grown on brain heart infusion media [94, 95].

Does the murine amniotic fluid contain a viable microbiota?

Forty-two amniotic fluid samples were cultured for bacteria, and only one amniotic fluid sample (Mouse #3 distal) yielded bacterial growth (**Figure 5A**). For this sample, multiple colonies of a single bacterial morphotype (Gram positive rod) were ultimately recovered under oxic and anoxic conditions. The partial 16S rRNA genes (703 bp) of these isolates were at least 99.7% identical to *Lactobacillus murinus* NBRC 14221 (NR_112689). The proximal and distal

amniotic fluid samples from Mouse #3 did not have 16S rDNA concentrations outside the range of other amniotic fluid samples in the study (**Figure 2A**).

Secondarily, for 13/21 mice for which culture was attempted, we characterized the 16S rDNA concentration and profile of the amniotic fluid-inoculated BHI broths, and compared these data to those of stock control broth. Overall, the 16S rDNA signal of inoculated broth did not exceed that of stock controls (**Figure 5B**). Additionally, the 16S rDNA profile structure of both the proximal and distal amniotic fluid cultures did not differ from those of the stock BHI control samples (PERMANOVA $F = 0.702$, $R^2 = 0.04$, $p = 0.602$ and $F = 0.918$, $R^2 = 0.051$, $p = 0.461$, respectively) (**Figure 5C and 5D**). Similar to the data for 16S rDNA concentration (**Figure 5B**), 16S rDNA profile did not differ between paired proximal and distal amniotic fluid samples (**Figure 5C and 5D**). However, many of these data from sequenced amniotic fluid culture samples may be DNA contaminants.

After removal of contaminants from the dataset using *decontam*, only half of the paired amniotic fluid culture samples ($N = 7$) had at least 500 sequence reads remaining. The structures of the proximal and distal culture 16S rDNA profiles did not vary by mouse ID (PERMANOVA $F = 0.815$, $R^2 = 0.409$, $p = 0.807$) or differ based on proximity to the cervix ($F = 1.057$, $R^2 = 0.089$, $p = 0.317$).

Taken together, using culture and molecular interrogation of culture broths, these data provide no evidence of bacterial growth in proximal or distal amniotic fluids.

DISCUSSION

In the current study, we utilized quantitative PCR, 16S rRNA gene sequencing, and bacterial culture to investigate the presence of bacterial signals in murine amniotic fluids. Molecular techniques indicated the presence of a 16S rDNA signal in the amniotic fluids; yet, this signal was not verified through culture as coming from a viable microbiota.

Prior reports of an amniotic fluid microbiota in normal human pregnancy

Investigations using quantitative PCR, 16S rRNA gene sequencing, or cultivation to determine the presence of a human amniotic fluid microbiota in normal pregnancy have yielded inconsistent findings [70, 72, 75-77, 84, 85, 91, 92, 96]. This is likely due in part to insufficient methods such as a lack of multiple complementary techniques for bacterial detection and isolation and/or a lack of appropriate technical controls. Notably, of these studies, only one reported the isolation of bacteria from human amniotic fluid of women who delivered a term neonate [72]. The bacteria that were isolated were *Propionibacterium* (*Cutibacterium*) and *Staphylococcus*. These bacteria were also identified in the 16S rRNA gene profiles of amniotic fluid; however, these bacteria are typical inhabitants of the human skin and may therefore represent skin contaminants [97].

Overall, of the studies that have performed 16S rRNA gene sequencing to investigate the existence of a human amniotic fluid microbiota in normal pregnancies [72, 75-77, 84, 85, 91, 92, 96], only five included technical controls for background DNA contamination [75, 76, 84, 91, 92]. Three concluded the existence of an amniotic fluid microbiota, although these studies did not include a culture component [75, 76, 84]. The first study [75] reported that 83.7% (36/43) of amniotic fluid samples had a 16S rDNA signal, with varying degrees of *Propionibacterium*

(*Cutibacterium*) *acnes*, *Staphylococcus epidermidis*, *Ralstonia*, *Streptococcus anginosus*, and *Peptoniphilus* dominance. The second study [76] reported that 19.9% (238/1,206) of amniotic fluid samples yielded a 16S rDNA signal; they were dominated by *Saccharibacteria*, *Acidovorax*, *Tepidimonas*, *Pelomonas*, and *Streptococcus oligofermentans*. In the third study [84], only 13.8% (4/29) of amniotic fluid samples had a detectable 16S rDNA signal, with *Actinomyces*, *Cutibacterium*, *Staphylococcus*, and *Streptococcus* being most relatively abundant. Thus, the most reported bacterial taxa detected in human amniotic fluid investigations were *Staphylococcus* and *Cutibacterium*, two typical skin bacteria [97]. These results illustrate the need for more comprehensive investigations using multiple complementary modes of microbiologic inquiry, as well as the need for appropriate technical controls.

Existence of an amniotic fluid microbiota in animal models

In cattle, three investigations utilized 16S rRNA gene sequencing to explore the presence of an amniotic fluid microbiota [98-100] (Table 2). Two concluded the existence of an amniotic fluid microbiota using this approach [98, 99]; however, one study, which also included qPCR and culture, concluded that the bacterial signals in the amniotic fluid did not exceed those in controls [100]. In two investigations of horses and goats, a microbiota was identified in the amniotic fluid using 16S rRNA gene sequencing [101, 102]. However, in a study of sheep, the amniotic fluid was determined to be sterile using qPCR and 16S rRNA gene sequencing [103].

In the only study to date of rodents [73], 16S rRNA gene sequencing was used to demonstrate that amniotic fluid microbiota profiles were pup- and dam-specific in a rat model, yet they were not different from those of the placenta or fetal intestine. The primary bacteria detected were identified as *Lachnospiraceae*, *Ruminococcaceae*, *Bacteroidaceae*,

Veillonellaceae, Rikenellaceae, and Propionibacteriaceae [73]. However, this study did not include qPCR or culture components.

Our findings in the context of prior studies

In the current study, quantitative PCR showed significantly greater 16S rRNA gene signal in both proximal and distal amniotic fluid samples than in the negative controls, indicating the presence of 16S rDNA in amniotic fluid samples regardless of proximity to the cervix. These findings are consistent with the qPCR results of a prior study of cattle amniotic fluid [99].

Our investigation using 16S rRNA gene sequencing detected higher relative abundances of DNA from *Corynebacterium* spp., *Pseudomonas*, *Sphingobium*, and *Streptococcus* in the amniotic fluid of mice than in controls (**Figure 3**). *Corynebacterium* spp. and *Streptococcus* spp. are resident microbiota of mammals, including humans and mice [97, 104-106]. However, these microorganisms have also been identified as common bacterial DNA contaminants in studies with low microbial biomass [84, 90]. *Corynebacterium* spp. are aerobic, non-spore-forming, Gram-positive bacteria [94] that have been identified as members of the mouse skin [106] and respiratory [105] microbiotas. Specifically, *Corynebacterium tuberculostearicum* (ASV 10) has been previously detected in human amniotic fluid using molecular techniques; however, this bacterium was not recovered using conventional culture methods [75, 107]. The *Streptococcus* ASV detected in the current study (ASV 13) had an identical sequence match with multiple members of the Mitis group of the genus *Streptococcus*, which are common inhabitants of the oral cavity and upper respiratory tract in humans [108] and have been detected in the lungs of mice [109]. *Pseudomonas* is widely distributed amongst mammals and the broader environment [110]. In our study, BLAST analysis was performed on ASV 24 (*Pseudomonas*), but a species-

level taxonomy could not be assigned, indicating that the V4 region of the 16S rRNA gene is not adequate for differentiation of *Pseudomonas* species. *Sphingobium* is typically an environmental microorganism [111]. In the current study, BLAST analysis for ASV 33 showed that it was identical to the typical soil bacteria *S. naphthae*, *S. olei*, and *S. soli* [112-114]. A single case was reported of *S. olei* causing peritonitis via infection of an indwelling peritoneal catheter in a patient with end stage renal disease [115]. In summary, although some of these microorganisms have been found in biologically relevant sites, the importance of their DNA signal in amniotic fluid in this study requires further investigation.

An inherent limitation of molecular investigations is the inability to differentiate between whether the presence of 16S rDNA signal is due to the presence of viable bacteria, dead cells, or environmental DNA. While many studies have used molecular techniques to confirm the existence of bacterial DNA in the placenta, fetal tissue, and amniotic fluid [48, 70, 72, 75-77, 84, 85, 91, 92, 96], only some have attempted to culture bacteria from these same samples [72, 85, 92, 96]. Notably, *Corynebacterium*, *Pseudomonas*, *Sphingobium*, *Streptococcus*, and other prominent bacteria identified in molecular surveys were not recovered in culture in this study. Indeed, the only microorganism that was cultured, *Lactobacillus murinus*, was not detected in the 16S rRNA gene profile of any amniotic fluid sample. *L. murinus* is known to reside in the GI system of mice, where it has been documented to play a role in attenuating inflammation [116]. Indeed, in a prior study [109], *L. murinus* was found in multiple body sites of pregnant mice. Given its wide distribution among and within mice, this *Lactobacillus* isolate may represent a culture contaminant.

Strengths of this study

The current study has three principal strengths. First, we used multiple, complementary modes of inquiry, including 16S rRNA gene qPCR, 16S rRNA gene sequencing, and bacterial culture to assess whether there is an amniotic fluid microbiota in mice. Furthermore, the culture component of the study included molecular validation. Second, we utilized robust sterile techniques as well as negative, experimental, and positive controls when performing extractions and molecular work to assure that any bacterial DNA signal detected in the experimental samples could be correctly attributed to a true 16S rDNA signal in the amniotic fluid versus environmental or reagent contamination. Third, we sampled amniotic fluid from amniotic sacs proximal and distal to the cervix for assessing differential presence of microorganisms throughout the uterine horns of mice.

Limitations of this study

The current study has two principal limitations. First, this study focused exclusively on assessing the presence of bacteria in murine amniotic fluid, whereas viruses and eukaryotic microorganisms were not considered in this study. Second, we used a specific animal model and therefore interpretation of results should consider the potential effect of variation in physiological and morphological characteristics among mouse strains and across animal facilities.

Conclusion

Using qPCR, 16S rRNA gene sequencing, and bacterial culture, we did not find consistent or reproducible evidence of an amniotic fluid microbiota in mice. This study provides evidence against amniotic fluid as a source of microorganisms for colonization of the fetus, and

312 illustrates the importance of using multiple methodologies and the appropriate technical controls
313 in investigations assessing microbial profiles of body sites historically presumed to be sterile.
314

MATERIALS AND METHODS

Study subjects

C57BL/6 mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA) and bred at the C.S. Mott Center for Human Growth and Development at Wayne State University, Detroit, MI, USA in the specific-pathogen-free (SPF) animal care facility. Mice were housed under a 12 h:12 h light/dark cycle and had access to food (PicoLab laboratory rodent diet 5L0D; LabDiet, St. Louis, MO, USA) and water *ad libitum*. Females (8-12 weeks old) were mated with males of demonstrated fertility. Daily examination was performed to assess the appearance of a vaginal plug, which indicated 0.5 days *post coitum* (dpc). Dams were then housed separately from the males and their weights were checked daily. An increase in weight of ≥ 2 g by 12.5 dpc confirmed pregnancy. All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) (Protocol No. 18-03-0584).

Sample collection and storage

Twenty-one pregnant mice were included in this study (**Figure 1**). Pregnant mice were euthanized during the second half of pregnancy (13.5-18.5 dpc). The abdomen was shaved, and 70% ethanol was applied. Dams were placed on a sterile surgical platform within a biological safety cabinet. Study personnel wore sterile sleeves, masks, and powder-free sterile gloves during sample collection, and sterile disposable scissors and forceps were utilized. Iodine was applied to the abdomen with a sterile cotton swab, and after the iodine dried a midline skin incision was performed along the full length of the abdomen. The peritoneum was longitudinally opened using a new set of scissors and forceps, and the uterine horns were separated from the cervix and placed within a sterile petri dish. A sterile syringe with a 26G needle was utilized to

obtain amniotic fluid from amniotic sacs proximal to the cervix and from amniotic sacs that were distal from the cervix. Due to the small volume of amniotic fluid often obtained from each amniotic sac (< 40 µl), amniotic fluid was obtained from two adjoining amniotic sacs and pooled. The amniotic fluid was aliquotted into two sterile tubes and transported immediately to the microbiology lab for bacterial culture and molecular analyses, respectively. The tube with the amniotic fluid for molecular analyses was stored at -80°C.

Culture of amniotic fluid samples

For all mice, proximal and distal amniotic fluid samples (~40 µL each) were cultured in 200 µL Brain-Heart-Infusion (BHI) broth supplemented with 5 mg/L of hemin and 2 µg/L of vitamin K under oxic and anoxic conditions for 48 hours. For the first eight mice in the study, 40 µL of the BHI culture was then plated on supplemented BHI agar plates and cultured under the respective atmospheric condition for an additional 48 hours, and resultant bacterial isolates were taxonomically characterized. For the last 13 mice in the study, 40 µL of the BHI culture was subsequently plated on supplemented BHI agar plates and cultured under the respective atmospheric condition if turbidity of the broth culture was observed after 48 hours of incubation. Any potential growth of bacteria in BHI broth cultures of proximal and distal amniotic fluid samples was then assessed through qPCR and 16S rRNA gene sequencing. As each amniotic fluid sample was cultured under oxic and anoxic conditions, 125 µL each from the oxic and anoxic broth cultures were pooled and stored at -80°C. The 16S rRNA gene loads and profiles of these amniotic fluid broth cultures were compared to those of six uninoculated BHI broth negative controls using qPCR and 16S rRNA gene sequencing.

DNA extraction

Genomic DNA was extracted within a biological safety cabinet from amniotic fluid and BHI broth samples, as well as positive (i.e., human clean catch urine (N=3) and negative (i.e., human amniotic fluid (N=3), sterile BHI broth (N=6), blank DNA extraction kits (N=14)) controls using the DNeasy PowerLyzer Powersoil kit (Qiagen, Germantown, MD, USA), with minor modifications to the manufacturer's protocols as previously described [109, 117]. Specifically, following UV treatment, 400 μ L of Powerbead solution, 200 μ L of phenol:chloroform:isoamyl alcohol (pH 7-8), and 60 μ L of preheated solution C1 were added to the provided bead tubes. Next, 250 μ L amniotic fluid or BHI sample were added to the tubes. When less than 250 μ L of amniotic fluid was available (9/41 samples, 21%) a minimum of 100 μ L was added. Tubes were briefly vortexed and cells were then mechanically lysed in a bead beater for two rounds of 30 sec each. Following 1 minute of centrifugation, supernatant was transferred to new tubes and 1 μ L of PureLinkTM RNase A (20mg/mL, Invitrogen), 100 μ L of solution C2, and 100 μ L of solution C3 were added. Tubes were then incubated at 4°C for 5 min. After a 1 min centrifugation, lysates were transferred to new tubes containing 650 μ L of C4 solution and 650 μ L of 100% ethanol. Lysates were then loaded onto filter columns 635 μ L at a time, centrifuged for 1 min, and the flowthrough discarded. This wash process was repeated three times to ensure all lysate passed through the filter columns. Following the wash steps, 500 μ L of solution C5 was added to the filter columns and centrifuged for 1 min. After discarding the flowthrough, the tubes were centrifuged for 2 min to dry the filter columns. The spin columns were transferred to clean 2.0 mL collection tubes and 60 μ L of pre-heated solution C6 was added directly to the center of the spin columns. Following a 5 min room temperature incubation, DNA

was eluted by centrifuging for 1 min. Purified DNA was then transferred to new 2.0 mL collection tubes and stored at -20°C.

16S rRNA gene quantitative real-time PCR

To measure total 16S rRNA gene abundance within samples, amplification of the V1-V2 region of the 16S rRNA gene was performed according to the protocol of Dickson et al. [118], with minor modifications as previously described [109, 117]. The modifications consisted of using a degenerative forward primer (27f-CM: 5'-AGA GTT TGA TCM TGG CTC AG-3') and degenerate probe with locked nucleic acids (+) (BSR65/17: [5'-56FAM-TAA +YA+C ATG +CA+A GT+C GA-BHQ1-3']). Each 20 µL reaction was performed with 0.6 µM of 27f-CM primer, 0.6 µM of 357R primer (5'-CTG CTG CCT YCC GTA G-3'), 0.25 µM of BSR65/17 probe, 10.0 µL of 2X TaqMan Environmental Master Mix 2.0 (Invitrogen), and 3.0 µL of purified DNA or nuclease-free water. The following conditions were used to perform the bacterial DNA qPCR: 95° C for 10 min, and then 40 cycles of 94°C for 30 sec, 50°C for 30 sec, and 72°C for 30 sec. Each reaction was performed in triplicate using an ABI 5500 thermocycler (Applied Biosystems, Foster City, CA, USA). After normalization to the ROX passive reference dye, the 7500 Software version 2.3 (Applied Biosystems, Foster City, CA, USA) was used to analyze the raw amplification data with the default threshold and baseline settings. Calculation of the cycle of quantification (Cq) values for the samples was based upon the mean number of cycles necessary for the exponential increase of normalized fluorescence.

16S rRNA gene sequencing

The V4 region of the 16S rRNA gene was amplified and sequenced via the dual indexing strategy developed by Kozich et al. [119]. The forward and reverse primers used were 515F: 5'-GTGCCAGCMGCCGCGGTAA-3' and 806R: 5'-GGACTACHVGGGTWTCTAAT-3', respectively. Duplicate 20 µL PCR reactions were performed containing 0.75 µM of each primer, 3.0 µL DNA template, 10.0 µL of DreamTaq High Sensitivity Master Mix (Thermo Scientific, Waltham, MA, USA), and 5 µL of DNase-free water. Reaction conditions were as follows: 95° for 3 min, followed by 38 cycles of 95°C for 45 sec, 50°C for 60 sec, and 72°C for 90 sec, followed by an additional elongation at 72°C for 10 min. The duplicate PCR reactions were then pooled, and DNA was quantified with a Qubit 3.0 fluorometer and Qubit dsDNA assay kit (Life Technologies, Carlsbad, CA) following the manufacturer's protocol. Samples were pooled in equimolar concentrations and purified using the Cytiva Sera-Mag Select DNA Size Selection and PCR Clean-Up Kit (Global Life Sciences, Little Chalfont, Buckinghamshire, UK) according to the manufacturer's instructions.

The R package *decontam* version 1.6.0 [120] was used to identify ASVs that were likely potential background DNA contaminants based on their distribution among biological samples (amniotic fluid and BHI cultures) and negative controls (blank DNA extractions and stock BHI broth) using the "IsNotContaminant" method. Identification of contaminant ASVs was assessed for amniotic fluid and BHI cultures independently. An ASV was determined to be a contaminant, and was removed from the dataset, if it had a *decontam* P score ≥ 0.7 and was present in at least 20% of negative controls with an overall average relative abundance of at least 1.0%

Statistical analysis

Prior to statistical analyses, the bacterial profiles of proximal and distal amniotic fluid samples and blank DNA extraction controls were rarefied to 1,366 sequence reads (set.seed = 1) using phyloseq [121]. The bacterial profiles of proximal and distal BHI culture samples and stock BHI broth samples were rarefied to 21,227 sequence reads. Variation in the bacterial profiles was visualized through Principal Coordinates Analyses (PCoA) using the R package vegan version 2.5-6 [122]. Alpha diversity values and 16S rDNA signal (qPCR Cq) values across sample groups were compared using the “wilcox.test” function in R version 3.6.0 [123]. Beta diversity of amniotic fluid bacterial profiles was characterized using the Bray-Curtis dissimilarity index. Bacterial community structure of amniotic fluid and BHI culture samples was compared using PERMANOVA [124] with the “adonis” function in the R package vegan version 2.5-6 [122]. Assessment of differentially abundant taxa across sample groups was performed using Linear Discriminant Analysis Effect Size, or LEfSe [125] with default parameters. Analysis of the phylogenetic relationships of selected ASVs and other bacteria was performed using the Neighbor-Joining method [126] in MEGA 6 software [127] with the Maximum Composite Likelihood method and bootstrapping of 1,000 replicates, allowing for transitions and transversions.

DATA AVAILABILITY

Sample-specific MiSeq run files have been deposited on the NCBI Sequence Read Archive (BioProject ID PRJNA751620).

447 **TABLES**

448 **Table 1. Description of prior molecular investigations of the human amniotic fluid.**

Authors & year	Sample size & collection	Culture conditions	qPCR target	Sequencing target & prominent bacteria	Controls for DNA contamination	Concluded existence of amniotic fluid microbiota
Rodriguez et al. 2011	N=121 amniotic fluid from amniocentesis during gestational weeks 16-20	Culture medium specific for ureaplasmas No cultivable biomass from amniotic fluid	N/A	No sequencing done Multiplex endpoint polymerase chain reaction of <i>Ureaplasma</i> specific urease gene for identification of <i>U. parvum</i> and <i>U. urealyticum</i>	N/A	YES
Rautava et al. 2012	N=14 Uncomplicated pregnancies at term Amniotic fluid collected during elective caesarean delivery	N/A	<i>Lactobacillus</i> , <i>Bifidobacterium</i> , <i>Bacteroides</i> , <i>Clostridium leptum</i> and <i>Clostridium coccoides</i>	N/A	N/A	YES
Collado et al. 2016	N=15 Healthy full-term women Amniotic fluid collected during elective caesarean delivery	Gifu anaerobic and LB media under anoxic atmospheres Isolated: <i>Staphylococcus</i> <i>Propionibacterium</i> <i>Lachnospiraceae</i> <i>Streptomyces</i>	N/A	16S rRNA gene <i>Enterobacteriaceae</i> , <i>Enterobacter</i> <i>Escherichia</i> <i>Propionibacterium</i> <i>Lactobacillus</i> <i>Streptococcus</i> <i>Staphylococcus</i>	N/A	YES
Lim et al. 2018	N=24 Uncomplicated pregnancies at term AF collected during elective caesarean	N/A	16S rRNA gene	16S rRNA gene	Blank DNA extraction kits (N=4) were sequenced.	NO

Rehbinder et al. 2018	N=10 Uncomplicated pregnancies at term Amniotic fluid collected during elective caesarean delivery	BHI medium under oxic and anoxic atmospheres No cultivable biomass from healthy amniotic fluid	16S rRNA gene	16S rRNA gene	Two negative controls were sequenced.	NO
Zhu et al. 2018	N=64 amniotic fluid samples 17-24 weeks karyotype amniocentesis N=50 for culture	BHI and Columbia Blood media under oxic atmosphere No cultivable biomass from amniotic fluid	N/A	16S rRNA gene <i>Propionibacterium</i> , Bacillales <i>Anoxybacillus</i> Caulobacteraceae Methylobacteriaceae <i>Methylobacterium</i> <i>Phyllobacterium</i> <i>Sphingomonas</i> Comamonadaceae <i>Deinococcus</i> Corynebacteriaceae Streptococcaceae	N/A	YES

Stinson et al. (a) 2019	N=43 Uncomplicated pregnancies at 34-42 weeks gestation Amniotic fluid collected during elective caesarean delivery	N/A	N/A	16S rRNA gene <i>Propionibacterium</i> <i>Staphylococcus</i> <i>Ralstonia</i> <i>Streptococcus</i> <i>Peptoniphilus</i> <i>Corynebacterium</i> spp.	Blank DNA extraction kits (N=5) were sequenced.	YES
Stinson et al. (b) 2020	N=18 Amniocentesis at 14-20 gestational weeks	N/A	16S rRNA gene Secondarily, <i>Ureaplasma</i>	16S rRNA gene <i>Saccharibacteria</i> <i>Acidovorax temperans</i> <i>Tepidimonas taiwanensis</i> <i>Pelomonas puraquae</i> <i>Corynebacterium</i> <i>Streptococcus</i> <i>Pseudomonas</i>	Blank DNA extraction kits (N=8) were sequenced.	YES
Campisciano et al. 2021	N=29 Amniocentesis at 15-21 weeks	N/A	N/A	16S rRNA gene <i>Acinetobacter</i> <i>Bacillus</i> <i>Stenotrophomonas</i> <i>Gemella</i> <i>Lactobacillus</i> <i>Mycoplasma</i> <i>Neisseria</i> <i>Ureaplasma</i> <i>Veillonella</i>	Blank DNA extraction kits (N=7) and a sterile swab were sequenced.	YES
Wu et al. 2021	N=25, Healthy, full-term women Amniotic fluid collected during elective caesarean delivery	N/A	N/A	16S rRNA gene <i>Sphingomonas</i> <i>Staphylococcus</i> <i>Streptococcus</i>	N/A	YES

450 **Table 2. Description of prior molecular investigations of an amniotic fluid microbiota using animal models.**
451

Animal model	Authors & year	Sample size & collection	Culture conditions	qPCR target	Sequencing target & prominent bacteria	Controls for DNA contamination	Concluded existence of amniotic fluid microbiota
Rat	Borghi et al 2019	N = 5 pups from 2 dams Gestational day 16/23 Cesarean delivery	N/A	N/A	16S rRNA gene Lachnospiraceae Ruminococcaceae Bacteroidaceae Veillonellaceae Rikenellaceae	Some blank extraction controls were sequenced and “known environmental contaminants were never observed.”	YES
Cattle	Moore et al 2017	N = 5 calves Third trimester Obtained following slaughter of cows	N/A	N/A	16S rRNA gene Clostridiales Ruminococcaceae S24-7 Lachnospiraceae <i>Flavobacterium</i>	N/A	YES
Cattle	Guzman et al 2020	N = 12 calves 5, 6, or 7 months / 9.4 months Obtained following slaughter of cows	N/A	16S rRNA gene	16S rRNA gene Flavobacteriales Rhodobacterales Xanthomonadales Enterobacteriales Sphingomonadales Pseudomonadales	Two blank extraction controls were sequenced, and these data were compared to amniotic fluid profiles (there was minimal overlap).	YES
Cattle	Husso et al 2021	N = 23 calves Term gestation Cesarean delivery prior to any rupture of membranes	Gifu Anaerobic Medium Agar under oxic and anoxic atmospheres	16S rRNA gene	16S rRNA gene <i>Staphylococcus*</i> <i>Streptococcus</i> <i>Delftia</i> <i>Sphingomonas*</i> <i>Enterococcus</i> * <i>Staphylococcus</i> and <i>Sphingomonas</i> were more relatively abundant in the profiles of amniotic fluid than the meconium.	Eight nuclease-free water controls were sequenced. <i>Decontam</i> was run.	NO
Sheep	Malmuthuge & Griebel 2018	N = 16 lambs Gestation day 125-135/144-152 Cesarean delivery	N/A	16S rRNA gene	16S rRNA gene	One PCR control was sequenced.	NO
Goat	Zou et al 2020	N = 3	N/A	N/A	16S rRNA gene	Three blank extraction controls were	YES

		Gestational day 90, 100, or 120 / 145-152 Cesarean delivery			Comamonadaceae Burkholderiales	sequenced and these data were used to determine which sequences should be removed from the dataset.	
Horse	Quercia et al 2019	N = 13 foals Gestational day 333-355/330-360 Vaginal delivery (needle puncture of the exposed amnion)	N/A	N/A	16S rRNA gene <i>Pseudomonas</i> <i>Sphingomonas</i> <i>Enterococcus</i> <i>Staphylococcus</i> <i>Erwinia</i> <i>Pedobacter</i>	None. However, previously identified contaminants constituted only a fraction of the bacterial profiles of amniotic fluid.	YES

452

FIGURE LEGENDS

Figure 1. Study design to test for the presence of bacteria in murine amniotic fluid.

Figure 2. 16S rDNA qPCR and sequencing results for amniotic fluid and blank control samples. (A) C_q values from qPCR of proximal and distal amniotic fluid and blank control (BLK) samples. (B) Principal coordinate analysis (PCoA) illustrating variation in 16S rRNA gene profiles among proximal and distal amniotic fluid and blank control samples. The 16S rRNA gene profiles were characterized using the Bray-Curtis similarity index. (C) Taxonomic classifications of the 20 amplicon sequence variants with highest relative abundance across all proximal and distal amniotic fluid and blank control samples.

Figure 3. Differentially abundant amplicon sequence variants (ASVs) in proximal and distal amniotic fluid and blank control samples. (A) proximal and (B) distal amniotic fluid samples compared to blank DNA extraction control samples as determined by Linear discriminant analysis effect size analyses. (C) Dendrogram of the three differentially abundant *Corynebacterium* ASVs in amniotic fluid samples and partial 16S rDNA sequences of closely related bacterial type strains. Numbers at the nodes are maximum-likelihood bootstrap values. Scale bar indicates the number of nucleotide substitutions per site.

Figure 4. Amniotic fluid sequencing results after the removal of likely contaminating sequences. (A) Bar graph showing the taxonomy of the 45 amplicon sequence variants with highest relative abundance across all proximal and distal amniotic samples. (B) Principal coordinate analysis (PCoA) illustrating variation in 16S rRNA gene profiles among proximal and distal amniotic fluid samples. The 16S rRNA gene profiles were characterized using the Bray-Curtis similarity index.

Figure 5. Amniotic fluid culture and blank control 16S rRNA gene qPCR and sequencing results. (A) Bacterial cultivation results for proximal and distal amniotic fluid samples. (B) Cycle of quantification values from qPCR on amniotic fluid culture samples and BHI culture medium controls. (C) Principal coordinate analysis (PCoA) of bacterial relative abundance data from amniotic fluid samples and BHI culture medium controls. (D) Relative abundance of bacteria in the 16S rRNA gene profiles of amniotic fluid samples and BHI culture medium controls.

REFERENCES

1. Schmidt, W., *The amniotic fluid compartment: the fetal habitat*. Advances in anatomy, embryology, and cell biology, 1992. **127**: p. 1-100.
2. Tarca, A.L., et al., *Amniotic fluid cell-free transcriptome: a glimpse into fetal development and placental cellular dynamics during normal pregnancy*. BMC Med Genomics, 2020. **13**(1): p. 25.
3. Lee, S.E., et al., *Evidence supporting proteolytic cleavage of insulin-like growth factor binding protein-1 (IGFBP-1) protein in amniotic fluid*. J Perinat Med, 2008. **36**(4): p. 316-23.
4. Romero, R., et al., *A potential role for epidermal growth factor/alpha-transforming growth factor in human parturition*. Eur J Obstet Gynecol Reprod Biol, 1989. **33**(1): p. 55-60.
5. Savasan, Z.A., et al., *Evidence in support of a role for anti-angiogenic factors in preterm prelabor rupture of membranes*. J Matern Fetal Neonatal Med, 2010. **23**(8): p. 828-41.
6. Romero, R., et al., *Infection and labor: III. Interleukin-1: A signal for the onset of parturition*. American Journal of Obstetrics and Gynecology, 1989. **160**(5, Part 1): p. 1117-1123.
7. Romero, R., et al., *Amniotic fluid interleukin-1 in spontaneous labor at term*. The Journal of reproductive medicine, 1990. **35**(3): p. 235-238.
8. ROMERO, R., et al., *Interleukin-1 α and Interleukin-1 β in Preterm and Term Human Parturition*. American Journal of Reproductive Immunology, 1992. **27**(3-4): p. 117-123.
9. Romero, R., et al., *Tumor necrosis factor in preterm and term labor*. Am J Obstet Gynecol, 1992. **166**(5): p. 1576-87.
10. Hillier, S.L., et al., *The relationship of amniotic fluid cytokines and preterm delivery, amniotic fluid infection, histologic chorioamnionitis, and chorioamnion infection*. Obstetrics and gynecology, 1993. **81**(6): p. 941-948.
11. Gomez, R., et al., *Premature Labor and Intra-Amniotic Infection: Clinical Aspects and Role of the Cytokines in Diagnosis and Pathophysiology*. Clinics in Perinatology, 1995. **22**(2): p. 281-342.
12. Yoon, B.H., et al., *Amniotic fluid cytokines (interleukin-6, tumor necrosis factor- α , interleukin-1 β , and interleukin-8) and the risk for the development of bronchopulmonary dysplasia*. American Journal of Obstetrics and Gynecology, 1997. **177**(4): p. 825-830.
13. Hsu, C.-D., et al., *Elevated Amniotic Fluid Nitric Oxide Metabolites and Interleukin-6 in Intra-amniotic Infection*. The Journal of the Society for Gynecologic Investigation: JSGI, 1998. **5**(1): p. 21-24.
14. Hsu, C.-D., et al., *Elevated amniotic fluid levels of leukemia inhibitory factor, interleukin 6, and interleukin 8 in intra-amniotic infection*. American Journal of Obstetrics and Gynecology, 1998. **179**(5): p. 1267-1270.
15. Hsu, C.-D., et al., *The role of amniotic fluid L-selectin, GRO- α , and interleukin-8 in the pathogenesis of intraamniotic infection*. American Journal of Obstetrics and Gynecology, 1998. **178**(3): p. 428-432.
16. González-Bosquet, E., et al., *Amniotic fluid glucose and cytokines values in the early diagnosis of amniotic infection in patients with preterm labor and intact membranes*. Journal of Maternal-Fetal Medicine, 1999. **8**(4): p. 155-158.
17. Maymon, E., et al., *Human neutrophil collagenase (matrix metalloproteinase 8) in parturition, premature rupture of the membranes, and intrauterine infection*. American Journal of Obstetrics and Gynecology, 2000. **183**(1): p. 94-99.
18. HSU, C.-D., K. AVERSA, and E. MEADDOUGH, *The Role of Amniotic Fluid Interleukin-6, and Cell Adhesion Molecules, Intercellular Adhesion Molecule-1 and Leukocyte Adhesion Molecule-1, in Intra-Amniotic Infection*. American Journal of Reproductive Immunology, 2000. **43**(5): p. 251-254.

19. Harirah, H., S.E. Donia, and C.-D. Hsu, *Amniotic fluid matrix metalloproteinase-9 and interleukin-6 in predicting intra-amniotic infection*. *Obstetrics & Gynecology*, 2002. **99**(1): p. 80-84.
20. Romero, R., et al., *Evidence of perturbations of the cytokine network in preterm labor*. *American Journal of Obstetrics and Gynecology*, 2015. **213**(6): p. 836.e1-836.e18.
21. Romero, R., et al., *Clinical chorioamnionitis at term II: the intra-amniotic inflammatory response*. *Journal of Perinatal Medicine*, 2016. **44**(1): p. 5-22.
22. Son, G.-H., et al., *Comparative Analysis of Midtrimester Amniotic Fluid Cytokine Levels to Predict Spontaneous Very Pre-term Birth in Patients with Cervical Insufficiency*. *American Journal of Reproductive Immunology*, 2016. **75**(2): p. 155-161.
23. Tarca, A.L., et al., *The cytokine network in women with an asymptomatic short cervix and the risk of preterm delivery*. *Am J Reprod Immunol*, 2017. **78**(3).
24. Chaemsaihong, P., et al., *Comparison of rapid MMP-8 and interleukin-6 point-of-care tests to identify intra-amniotic inflammation/infection and impending preterm delivery in patients with preterm labor and intact membranes*. *The Journal of Maternal-Fetal & Neonatal Medicine*, 2018. **31**(2): p. 228-244.
25. Gomez-Lopez, N., et al., *Inflammasome activation during spontaneous preterm labor with intra-amniotic infection or sterile intra-amniotic inflammation*. *American Journal of Reproductive Immunology*, 2018. **80**(5): p. e13049.
26. Musilova, I., et al., *Interleukin-6 measured using the automated electrochemiluminescence immunoassay method for the identification of intra-amniotic inflammation in preterm prelabor rupture of membranes*. *The Journal of Maternal-Fetal & Neonatal Medicine*, 2020. **33**(11): p. 1919-1926.
27. Bhatti, G., et al., *Compartmentalized profiling of amniotic fluid cytokines in women with preterm labor*. *PLoS One*, 2020. **15**(1): p. e0227881.
28. Espinoza, J., et al., *Antimicrobial peptides in amniotic fluid: defensins, calprotectin and bacterial/permeability-increasing protein in patients with microbial invasion of the amniotic cavity, intra-amniotic inflammation, preterm labor and premature rupture of membranes*. *The Journal of Maternal-Fetal & Neonatal Medicine*, 2003. **13**(1): p. 2-21.
29. Yoshio, H., et al., *Antimicrobial Polypeptides of Human Vernix Caseosa and Amniotic Fluid: Implications for Newborn Innate Defense*. *Pediatric Research*, 2003. **53**(2): p. 211-216.
30. Soto, E., et al., *Human β -defensin-2: A natural antimicrobial peptide present in amniotic fluid participates in the host response to microbial invasion of the amniotic cavity*. *The Journal of Maternal-Fetal & Neonatal Medicine*, 2007. **20**(1): p. 15-22.
31. Iavazzo, C., et al., *The role of human beta defensins 2 and 3 in the second trimester amniotic fluid in predicting preterm labor and premature rupture of membranes*. *Archives of Gynecology and Obstetrics*, 2010. **281**(5): p. 793-799.
32. Varrey, A., et al., *Human β -defensin-1: A natural antimicrobial peptide present in amniotic fluid that is increased in spontaneous preterm labor with intra-amniotic infection*. *American Journal of Reproductive Immunology*, 2018. **80**(4): p. e13031.
33. Para, R., et al., *Human β -defensin-3 participates in intra-amniotic host defense in women with labor at term, spontaneous preterm labor and intact membranes, and preterm prelabor rupture of membranes*. *J Matern Fetal Neonatal Med*, 2020. **33**(24): p. 4117-4132.
34. Gomez-Lopez, N., et al., *The immunophenotype of amniotic fluid leukocytes in normal and complicated pregnancies*. *American Journal of Reproductive Immunology*, 2018. **79**(4): p. e12827.
35. Gomez-Lopez, N., et al., *Cellular immune responses in amniotic fluid of women with preterm labor and intra-amniotic infection or intra-amniotic inflammation*. *Am J Reprod Immunol*, 2019. **82**(5): p. e13171.

36. Gomez-Lopez, N., et al., *Fetal T Cell Activation in the Amniotic Cavity during Preterm Labor: A Potential Mechanism for a Subset of Idiopathic Preterm Birth*. J Immunol, 2019. **203**(7): p. 1793-1807.
37. Galaz, J., et al., *Cellular immune responses in amniotic fluid of women with preterm prelabor rupture of membranes*. J Perinat Med, 2020. **48**(3): p. 222-233.
38. Galaz, J., et al., *Cellular immune responses in amniotic fluid of women with a sonographic short cervix*. J Perinat Med, 2020. **48**(7): p. 665-676.
39. Galaz, J., et al., *Cellular immune responses in amniotic fluid of women with preterm clinical chorioamnionitis*. Inflamm Res, 2020. **69**(2): p. 203-216.
40. Martinez-Varea, A., et al., *Clinical chorioamnionitis at term VII: the amniotic fluid cellular immune response*. Journal of Perinatal Medicine, 2017. **45**(5): p. 523-538.
41. Romero, R., et al., *Amniotic fluid prostaglandin levels and intra-amniotic infections*. Lancet (London, England), 1986. **1**(8494): p. 1380.
42. Romero, R., et al., *The value and limitations of the Gram stain examination in the diagnosis of intraamniotic infection*. American journal of obstetrics and gynecology, 1988. **159**(1): p. 114-119.
43. Romero, R., et al., *Diagnosis of intra-amniotic infection: the acridine orange stain*. American journal of perinatology, 1989. **6**(1): p. 41-45.
44. Romero, R., et al., *Infection and labor. V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes*. American journal of obstetrics and gynecology, 1989. **161**(3): p. 817-824.
45. Romero, R., et al., *Amniotic fluid glucose concentration: a rapid and simple method for the detection of intraamniotic infection in preterm labor*. American journal of obstetrics and gynecology, 1990. **163**(3): p. 968-974.
46. Romero, R., et al., *Amniotic fluid white blood cell count: a rapid and simple test to diagnose microbial invasion of the amniotic cavity and predict preterm delivery*. American journal of obstetrics and gynecology, 1991. **165**(4 Pt 1): p. 821-830.
47. Romero, R., et al., *Amniotic fluid interleukin-6 determinations are of diagnostic and prognostic value in preterm labor*. American journal of reproductive immunology (New York, N.Y. : 1989), 1993. **30**(2-3): p. 167-183.
48. Gomez, R., et al., *The value of amniotic fluid interleukin-6, white blood cell count, and gram stain in the diagnosis of microbial invasion of the amniotic cavity in patients at term*. American journal of reproductive immunology (New York, N.Y. : 1989), 1994. **32**(3): p. 200-210.
49. Yoon, B.H., et al., *Clinical implications of detection of Ureaplasma urealyticum in the amniotic cavity with the polymerase chain reaction*. American journal of obstetrics and gynecology, 2000. **183**(5): p. 1130-1137.
50. Yoon, B.H., et al., *Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes*. American journal of obstetrics and gynecology, 2001. **185**(5): p. 1130-1136.
51. Romero, R., et al., *A novel molecular microbiologic technique for the rapid diagnosis of microbial invasion of the amniotic cavity and intra-amniotic infection in preterm labor with intact membranes*. American journal of reproductive immunology (New York, N.Y. : 1989), 2014. **71**(4): p. 330-358.
52. Romero, R., et al., *Prevalence and clinical significance of sterile intra-amniotic inflammation in patients with preterm labor and intact membranes*. American journal of reproductive immunology (New York, N.Y. : 1989), 2014. **72**(5): p. 458-474.
53. Romero, R., et al., *Sterile intra-amniotic inflammation in asymptomatic patients with a sonographic short cervix: prevalence and clinical significance*. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal

- Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2015. **28**(11): p. 1343-1359.
54. Romero, R., et al., *Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes*. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2015. **28**(12): p. 1394-1409.
55. Romero, R., et al., *Clinical chorioamnionitis at term I: microbiology of the amniotic cavity using cultivation and molecular techniques*. Journal of perinatal medicine, 2015. **43**(1): p. 19-36.
56. Chaemsathong, P., et al., *A point of care test for interleukin-6 in amniotic fluid in preterm prelabor rupture of membranes: a step toward the early treatment of acute intra-amniotic inflammation/infection*. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2016. **29**(3): p. 360-367.
57. Chaemsathong, P., et al., *A rapid interleukin-6 bedside test for the identification of intra-amniotic inflammation in preterm labor with intact membranes*. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2016. **29**(3): p. 349-359.
58. Chaiyasit, N., et al., *Clinical chorioamnionitis at term VIII: a rapid MMP-8 test for the identification of intra-amniotic inflammation*. Journal of perinatal medicine, 2017. **45**(5): p. 539-550.
59. Romero, R., et al., *Evidence that intra-amniotic infections are often the result of an ascending invasion - a molecular microbiological study*. J Perinat Med, 2019. **47**(9): p. 915-931.
60. Romero, R., S.K. Dey, and S.J. Fisher, *Preterm labor: one syndrome, many causes*. Science, 2014. **345**(6198): p. 760-5.
61. Yoder, P.R., et al., *A prospective, controlled study of maternal and perinatal outcome after intra-amniotic infection at term*. Am J Obstet Gynecol, 1983. **145**(6): p. 695-701.
62. Romero, R., et al., *Microbial invasion of the amniotic cavity during term labor. Prevalence and clinical significance*. The Journal of reproductive medicine, 1993. **38**(7): p. 543-548.
63. Espinoza, J., et al., *The prevalence and clinical significance of amniotic fluid 'sludge' in patients with preterm labor and intact membranes*. Ultrasound Obstet Gynecol, 2005. **25**(4): p. 346-52.
64. DiGiulio, D.B., et al., *Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes*. Am J Reprod Immunol, 2010. **64**(1): p. 38-57.
65. Kacerovsky, M., et al., *Prelabor rupture of membranes between 34 and 37 weeks: the intraamniotic inflammatory response and neonatal outcomes*. Am J Obstet Gynecol, 2014. **210**(4): p. 325 e1-325 e10.
66. Musilova, I., et al., *Late preterm prelabor rupture of fetal membranes: fetal inflammatory response and neonatal outcome*. Pediatr Res, 2018. **83**(3): p. 630-637.
67. Thorell, A., et al., *Microbial invasion of the amniotic cavity is associated with impaired cognitive and motor function at school age in preterm children*. Pediatr Res, 2020. **87**(5): p. 924-931.
68. Perez-Muñoz, M.E., et al., *A critical assessment of the "sterile womb" and "in utero colonization" hypotheses: implications for research on the pioneer infant microbiome*. Microbiome, 2017. **5**(1): p. 48.
69. DiGiulio, D.B., et al., *Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation*. PLoS One, 2008. **3**(8): p. e3056.

677 70. Rautava, S., et al., *Probiotics modulate host-microbe interaction in the placenta and fetal gut: a*
678 *randomized, double-blind, placebo-controlled trial*. Neonatology, 2012. **102**(3): p. 178-84.
679 71. Combs, C.A., et al., *Amniotic fluid infection, inflammation, and colonization in preterm labor with*
680 *intact membranes*. Am J Obstet Gynecol, 2014. **210**(2): p. 125.e1-125.e15.
681 72. Collado, M.C., et al., *Human gut colonisation may be initiated in utero by distinct microbial*
682 *communities in the placenta and amniotic fluid*. Sci Rep, 2016. **6**: p. 23129.
683 73. Borghi, E., et al., *Antenatal Microbial Colonization of Mammalian Gut*. Reprod Sci, 2019. **26**(8): p.
684 1045-1053.
685 74. Liu, C.J., et al., *Is the delivery mode a critical factor for the microbial communities in the*
686 *meconium?* EBioMedicine, 2019. **49**: p. 354-363.
687 75. Stinson, L.F., et al., *The Not-so-Sterile Womb: Evidence That the Human Fetus Is Exposed to*
688 *Bacteria Prior to Birth*. Front Microbiol, 2019. **10**: p. 1124.
689 76. Stinson, L., et al., *Comparison of Bacterial DNA Profiles in Mid-Trimester Amniotic Fluid Samples*
690 *From Preterm and Term Deliveries*. Front Microbiol, 2020. **11**: p. 415.
691 77. Wu, S., et al., *Do Maternal Microbes Shape Newborn Oral Microbes?* Indian J Microbiol, 2021.
692 **61**(1): p. 16-23.
693 78. Mackie, R.I., A. Sghir, and H.R. Gaskins, *Developmental microbial ecology of the neonatal*
694 *gastrointestinal tract*. Am J Clin Nutr, 1999. **69**(5): p. 1035s-1045s.
695 79. Moore, T.A., C.K. Hanson, and A. Anderson-Berry, *Colonization of the Gastrointestinal Tract in*
696 *Neonates: A Review*. ICAN: Infant, Child, & Adolescent Nutrition, 2011. **3**(5): p. 291-295.
697 80. Walker, W.A., *Initial intestinal colonization in the human infant and immune homeostasis*. Ann
698 Nutr Metab, 2013. **63** Suppl 2: p. 8-15.
699 81. Miniello, V.L., et al., *Gut microbiota biomodulators, when the stork comes by the scalpel*. Clin
700 Chim Acta, 2015. **451**(Pt A): p. 88-96.
701 82. Stokholm, J., et al., *Cesarean section changes neonatal gut colonization*. J Allergy Clin Immunol,
702 2016. **138**(3): p. 881-889.e2.
703 83. Blaser, M.J., et al., *Lessons learned from the prenatal microbiome controversy*. Microbiome,
704 2021. **9**(1): p. 8.
705 84. Campisciano, G., et al., *Evidence of bacterial DNA presence in chorionic villi and amniotic fluid in*
706 *the first and second trimester of pregnancy*. Future Microbiol, 2021. **16**: p. 801-810.
707 85. Zhu, L., et al., *Bacterial Communities in the Womb During Healthy Pregnancy*. Front Microbiol,
708 2018. **9**: p. 2163.
709 86. Satokari, R., et al., *Bifidobacterium and Lactobacillus DNA in the human placenta*. Lett Appl
710 Microbiol, 2009. **48**(1): p. 8-12.
711 87. Gomez de Agüero, M., et al., *The maternal microbiota drives early postnatal innate immune*
712 *development*. Science, 2016. **351**(6279): p. 1296-302.
713 88. Martinez, K.A., 2nd, et al., *Bacterial DNA is present in the fetal intestine and overlaps with that in*
714 *the placenta in mice*. PLoS One, 2018. **13**(5): p. e0197439.
715 89. Kliman, H.J., *Comment on "the placenta harbors a unique microbiome"*. Sci Transl Med, 2014.
716 **6**(254): p. 254le4.
717 90. Salter, S.J., et al., *Reagent and laboratory contamination can critically impact sequence-based*
718 *microbiome analyses*. BMC Biol, 2014. **12**: p. 87.
719 91. Lim, E.S., C. Rodriguez, and L.R. Holtz, *Amniotic fluid from healthy term pregnancies does not*
720 *harbor a detectable microbial community*. Microbiome, 2018. **6**(1): p. 87.
721 92. Reh binder, E.M., et al., *Is amniotic fluid of women with uncomplicated term pregnancies free of*
722 *bacteria?* Am J Obstet Gynecol, 2018. **219**(3): p. 289.e1-289.e12.
723 93. Pulendran, B. and M.M. Davis, *The science and medicine of human immunology*. Science, 2020.
724 **369**(6511).

94. Bernard, K.A. and G. Funke, *Corynebacterium*, in *Bergey's manual of systematics of Archaea and Bacteria*, W.B. Whitman, Editor. 2015, John Wiley & Sons: Hoboken, New Jersey. p. 1-70.
95. Torres, I., et al., *Short-term incubation of positive blood cultures in brain-heart infusion broth accelerates identification of bacteria by matrix-assisted laser desorption/ionization time-of-flight mass-spectrometry*. J Med Microbiol, 2017. **66**(12): p. 1752-1758.
96. Rodríguez, N., et al., *Detection of Ureaplasma urealyticum and Ureaplasma parvum in amniotic fluid: association with pregnancy outcomes*. J Matern Fetal Neonatal Med, 2011. **24**(1): p. 47-50.
97. Grice, E.A. and J.A. Segre, *The skin microbiome*. Nat Rev Microbiol, 2011. **9**(4): p. 244-53.
98. Moore, S.G., et al., *Hot topic: 16S rRNA gene sequencing reveals the microbiome of the virgin and pregnant bovine uterus*. J Dairy Sci, 2017. **100**(6): p. 4953-4960.
99. Guzman, C.E., et al., *A pioneer calf foetus microbiome*. Sci Rep, 2020. **10**(1): p. 17712.
100. Husso, A., et al., *The Composition of the Microbiota in the Full-Term Fetal Gut and Amniotic Fluid: A Bovine Cesarean Section Study*. Front Microbiol, 2021. **12**: p. 626421.
101. Quercia, S., et al., *Early colonisation and temporal dynamics of the gut microbial ecosystem in Standardbred foals*. Equine Vet J, 2019. **51**(2): p. 231-237.
102. Zou, X., et al., *Exploring the Rumen and Cecum Microbial Community from Fetus to Adulthood in Goat*. Animals (Basel), 2020. **10**(9).
103. Malmuthuge, N. and P.J. Griebel, *Fetal environment and fetal intestine are sterile during the third trimester of pregnancy*. Vet Immunol Immunopathol, 2018. **204**: p. 59-64.
104. Deo, P.N. and R. Deshmukh, *Oral microbiome: Unveiling the fundamentals*. J Oral Maxillofac Pathol, 2019. **23**(1): p. 122-128.
105. Kanmani, P., et al., *Respiratory Commensal Bacteria Corynebacterium pseudodiphtheriticum Improves Resistance of Infant Mice to Respiratory Syncytial Virus and Streptococcus pneumoniae Superinfection*. Front Microbiol, 2017. **8**: p. 1613.
106. Belheouane, M., et al., *Improved detection of gene-microbe interactions in the mouse skin microbiota using high-resolution QTL mapping of 16S rRNA transcripts*. Microbiome, 2017. **5**(1): p. 59.
107. Jung, E., et al., *Bacteria in the amniotic fluid without inflammation: early colonization vs. contamination*. Journal of Perinatal Medicine, 2021(000010151520210191).
108. Zheng, W., et al., *StreptoBase: An Oral Streptococcus mitis Group Genomic Resource and Analysis Platform*. PLoS One, 2016. **11**(5): p. e0151908.
109. Theis, K.R., et al., *No Consistent Evidence for Microbiota in Murine Placental and Fetal Tissues*. mSphere, 2020. **5**(1).
110. Palleroni, N.J., *Pseudomonas*. Bergey's manual of systematics of archaea and bacteria, 2015: p. 1-1.
111. Singhvi, N., et al., *Sphingobium*, in *Bergey's manual of systematics of Archaea and Bacteria*, W.B. Whitman, Editor. 2021, John Wiley & Sons: Hoboken, New Jersey.
112. Young, C.C., et al., *Sphingobium olei sp. nov., isolated from oil-contaminated soil*. Int J Syst Evol Microbiol, 2007. **57**(Pt 11): p. 2613-2617.
113. Du, J., et al., *Sphingobium soli sp. nov. isolated from rhizosphere soil of a rose*. Antonie Van Leeuwenhoek, 2015. **108**(5): p. 1091-7.
114. Chaudhary, D.K., S.-W. Jeong, and J. Kim, *Sphingobium naphthae sp. nov., with the ability to degrade aliphatic hydrocarbons, isolated from oil-contaminated soil*. International Journal of Systematic and Evolutionary Microbiology, 2017. **67**(8): p. 2986-2993.
115. Ruiter, N.M., et al., *Sphingobium olei peritonitis: peritoneal dialysis in turmoil?* Perit Dial Int, 2013. **33**(1): p. 102-3.
116. Pan, F., et al., *Predominant gut Lactobacillus murinus strain mediates anti-inflammaging effects in calorie-restricted mice*. Microbiome, 2018. **6**(1): p. 54.

773 117. Theis, K.R., et al., *Lack of Evidence for Microbiota in the Placental and Fetal Tissues of Rhesus*
774 *Macaques*. mSphere, 2020. **5**(3).
775 118. Dickson, R.P., et al., *Changes in the lung microbiome following lung transplantation include the*
776 *emergence of two distinct Pseudomonas species with distinct clinical associations*. PLoS One,
777 2014. **9**(5): p. e97214.
778 119. Kozich, J.J., et al., *Development of a dual-index sequencing strategy and curation pipeline for*
779 *analyzing amplicon sequence data on the MiSeq Illumina sequencing platform*. Appl Environ
780 Microbiol, 2013. **79**(17): p. 5112-20.
781 120. Davis, N.M., et al., *Simple statistical identification and removal of contaminant sequences in*
782 *marker-gene and metagenomics data*. Microbiome, 2018. **6**(1): p. 226.
783 121. McMurdie, P.J. and S. Holmes, *phyloseq: an R package for reproducible interactive analysis and*
784 *graphics of microbiome census data*. PLoS One, 2013. **8**(4): p. e61217.
785 122. Oksanen, J., et al., *vegan: Community ecology package*. R package version 2.5-6. 2019, R
786 Foundation for Statistical Computing.
787 123. Team, R.C., *R: A language and environment for statistical computing*. 2013.
788 124. Anderson, M.J., *Permutational multivariate analysis of variance*. Department of Statistics,
789 University of Auckland, Auckland, 2005. **26**: p. 32-46.
790 125. Segata, N., et al., *Metagenomic biomarker discovery and explanation*. Genome Biol, 2011. **12**(6):
791 p. R60.
792 126. Saitou, N. and M. Nei, *The neighbor-joining method: a new method for reconstructing*
793 *phylogenetic trees*. Mol Biol Evol, 1987. **4**(4): p. 406-25.
794 127. Tamura, K., et al., *MEGA6: Molecular Evolutionary Genetics Analysis version 6.0*. Mol Biol Evol,
795 2013. **30**(12): p. 2725-9.

796

A Proximal Negative Control

B Distal Negative Control

C

Distal Control

Abundance

NEG1 NEG2 NEG3 NEG4 NEG5 NEG6

Proximal

Abundance

Mouse #9 Mouse #10 Mouse #11 Mouse #12 Mouse #13 Mouse #14 Mouse #15 Mouse #16 Mouse #17 Mouse #18 Mouse #19 Mouse #20 Mouse #21

Distal

Abundance

Mouse #9 Mouse #10 Mouse #11 Mouse #12 Mouse #13 Mouse #14 Mouse #15 Mouse #16 Mouse #17 Mouse #18 Mouse #19 Mouse #20 Mouse #21

Legend:

- Acinetobacter
- Bacillaceae
- Bradyrhizobium
- Brevibacillus
- Enterobacteriaceae
- Enterococcus
- Gardnerella
- Lactobacillus
- Lactococcus
- Proteus
- Shuttleworthia
- Staphylococcus